top of page

our solutions:

Phage-based precision antimicrobials:
fast and effective

jumbo_kinzbio.png

At Kinzbio, we create phage-based treatments and prevention solutions to tackle

antibiotic-resistant infections. Our platform allows us to deliver (semi) personalized, pharmaceutical-grade therapies in just 5-15 days,

based on the specific bacteria causing the patient’s infection. 

 

We also develop solutions to prevent infections in hospitals and ICUs.

jumbo_kinzbio.png

We combine patents, proprietary databases, biobanks and AI-driven software to identify and optimize phages for medical and industrial applications, giving us a strong advantage in precision antimicrobials.

what sets us apart?

Our approach is:

​

  • Personalized: Tailored to the specific needs of each patient or process.

  • Adaptable: Capable of adjusting to emerging challenges.​

  • Fast: Delivering solutions in just 5–15 days.

  • Environmentally friendly and
    health-conscious: naturally safe for the environment and highly specific in targeting only harmful bacteria.

  • Highly specific: Targeting only the bacteria responsible for the infection, without affecting beneficial microbes.

OUR PROGRESS SO FAR

successful treatments

Successfully treated the first patients in Uruguay, achieving complete bacterial eradication after phage therapy for various medical conditions such as ventilator-associated pneumonia, urinary tract infections, and prosthetic joint infections.

New opportunities

support

Our technology and strategy have received validation and support from esteemed international incubators and accelerators like INCATE and Eretz.Bio (Albert Einstein Hospital), which are aiding in our next steps.

Regulatory development

We established a specific regulatory framework in collaboration with the local Ministry of Health, aligned with international regulations being developed in Europe and the U.S.

jumbo_kinzbio.png
jumbo_kinzbio.png
jumbo_kinzbio.png
jumbo_kinzbio.png
5d49a6ba7f3cb-xs.png
MSP_LOGOTIPO_2020_HORIZONTAL_POSITIVO.jpg

We’re exploring new markets in Brasil, Europe and Colombia, where a team member is actively assessing business and commercialization prospects.

unleashing the potential of

phages together

Kinzbio fosters collaborations and partnerships with pharma leaders, clinical organizations, academic labs and funding agencies to help the company to accelerate the development of its phage platform and pipeline.

 

Kinzbio has an open communication channel with and is always seeking to hear from industry partners and funding institutions interested in joining efforts to keep developing applications based on the biology of phages.

BE IN

TOUCH

Please fill your contact details below:

Thanks for contacting us!

Phage technologies for a healthier world

We are launching the first medical congress in Uruguay focused on the latest developments in Phage therapy.

c1ece665a7319e22602d0d90426d3be5_edited_

ANtimicrobial
resistance is one
of the major global
health issues that
humanity is facing

every year millions
of lives are lost and
billions are spent in
prevention and
treatment of AMR

Microbiome_edited.png
3305040.png
3305040.png
3305040.png
3305040.png
3305040.png

phages are natural
bacterial killers
that can be used to
combat AMR pathogens

Kinzbio created an innovative
technology platform
designed to develop phage-based
precision antimicrobials for
the treatment and prevention
of infections caused by
top-priority AMR pathogens. 

c1ece665a7319e22602d0d90426d3be5_edited_
Microbiome_edited.png

In 2024 we began offering
phage therapy for clinical use,
following approval from
Uruguay's Ministry of Public Health

Contact

6201 Avenida Italia

Montevideo 11500

Uruguay

 

E-mail: info@kinzbio.com

Whatsapp: +598-99856131

Supported by

bottom of page